OBJECTIVES: Transapical aortic valve implantation (TA-AVI) using the Edwards SAPIEN™ prosthesis has evolved into a routine procedure for selected high-risk elderly patients. The recently introduced SAPIEN™ delivery system (Ascendra II+™) with an added nose cone seems to facilitate direct valve implantation without prior balloon valvuloplasty (BAV). Here, we report our initial experience with this device.
INTRODUCTION
Transcatheter aortic valve implantation (TAVI) has surpassed the learning curve that is frequently associated with the introduction of new technologies. TAVI using either a retrograde trans-femoral (TF) or an antegrade transapical (TA) approach as well as other alternative access options is nowadays considered to be a highly standardized and reproducible treatment option for elderly highrisk patients [1] [2] [3] [4] [5] .
In TAVI procedures, it has been common practice to first perform a balloon valvuloplasty (BAV) followed by implantation of a 'valved stent'. When using the balloon-expandable SAPIEN™ prosthesis, the main purpose of the initial BAV is to 'open up' the stenotic native aortic valve in order to allow access for the relatively bulky delivery system housing the crimped valve.
Recently, a new delivery system for the SAPIEN XT™ prosthesis has become available. The refined Ascendra II+™ delivery catheter adds a nose-cone tip primarily designed to ease valve crossing for retrograde transaortic implantations [6] (Fig. 1) . The new design feature enables a smoother transition from the tip over the crimped valve and to the integrated 'pusher', which is purported to facilitate TA antegrade valve positioning and implantation without prior BAV. In this series, we present our initial clinical experience with this new technique of 'direct valve stenting' omitting prior BAV. Results are analysed by means of propensity score (PS) matching in comparison with the standard technique focusing on short-term functional and clinical outcomes.
METHODS

Patients
From March 2012 until July 2013, 128 patients with symptomatic aortic stenosis (AS) were scheduled for native TA aortic valve implantation (AVI) using an Edwards SAPIEN XT™ prosthesis. Valves were implanted using either the standard technique (including prior BAV: 'BAV group') or without BAV using a 'direct valvestenting' technique ('no-BAV group').
All cases (n = 128) were included in the overall analysis and constitute Cohort I. To be able to further adjust for the degree of valve calcification, we also analysed a subset of those patients having a complete record of cardio-computed tomography (CT) data. The latter group will be referred to hereafter as Cohort II (n = 79). Preoperative characteristics of both cohorts are presented in Tables 1 and 3 .
Indication for TAVI was discussed within an interdisciplinary team and all procedures were performed by a Heart team.
Study end point definitions
The primary study end points were haemodynamic valve performance, requirement for balloon redilatation, necessity for pacemaker implantation and occurrence of neurological events. Secondary study end points were the amount of contrast dye, fluoroscopy time, valve-in-valve rescue procedure, left ventricular ejection fraction at discharge and 30-day mortality.
Transient ischaemic attack (TIA) was defined as any new focal neurological deficit that resolved completely within 24 h. Any new, longer-lasting deficit was considered to be a stroke.
Cardio-computed tomography measurements
Prior to TAVI multi-slice CT (MSCT) examinations of the thoracic aorta were accomplished with a dual source 2 × 64 slice scanner (Siemens Medical Solutions, Erlangen, Germany). Calcium scans and contrast-enhanced scans were obtained under the following conditions: 120 kV, 320-400 effective mAs, pitch 0.2, rotation time 164 or 330 ms and detector aperture 0.6 mm. Reconstruction of calcium scans was performed with a B25f cardiac-gated reconstruction algorithm at 70% R-R cardiac cycle with a slice thickness of 3 mm. Contrast-enhanced scans were acquired by intravenous administration of Solutrast 370 (Iopamidol, 370 mg iodine/ml, Bracco Imaging Deutschland GmbH, Konstanz, Germany) in an antecubital vein using 80-120 ml with a flow of 4 ml/s followed by a bolus of 50 ml isotonic saline with equal flow. Scan timing was coordinated by peak enhancement detection with region of interest in the ascending aorta choosing a threshold of 120 Houndsfield Units (HU). For image reconstruction, a B26f cardiac-gated reconstruction algorithm at 70% of cardiac cycle was used with a slice thickness of 0.75 mm. Image analysis was carried out on a Syngo workstation (Siemens Medical Solutions, Erlangen, Germany). The calcium Table 3 : Baseline data of patients with valid cardio-CT data: Cohort II before and after propensity score matching adjustment ADULT CARDIAC score of the aortic valve was calculated according to the Agatston method with a threshold of 130 HU in a transverse plane.
Implantation technique
All procedures were performed in a fully equipped and modified catheterization laboratory. TA access was gained as described previously [7] . DynaCT [8] technology was used to obtain optimal C-arm angulation. After standard antegrade guidewire positioning, a BAV using the standard Edwards 20-mm balloon provided within the valve kit was performed in all BAV-group patients over a 20-F soft-tip sheath.
In the next step, the delivery sheath was inserted into the ventricle and the Ascendra II™ system was connected and deaired following the standard protocol. The SAPIEN XT™ prosthesis was advanced through the native valve and positioned within the aortic annulus. Care was taken to centre the valve during antegrade crossing by means of wire manipulations (slack/tension). Valve implantation was performed as usual under rapid pacing using a step-wise inflation technique.
Functional results were assessed by aortic root angiography and transesophageal echocardiography in all patients. Balloon redilatation was performed only if a relevant paravalvular leak was observed despite optimal valve position. In cases where there was residual relevant leak potentially caused by suboptimal prosthesis position, a second SAPIEN XT™ valve was implanted as a rescue valve-in-valve procedure [9] .
After routine apical and chest wall closure, patients were extubated on the table and transferred to an intermediate care unit following an ultra-fast-track protocol.
Follow-up
All patients underwent echocardiographic examination before discharge; follow-up data were available for up to 1 month.
Statistics
All continuous data are presented as mean and 95% confidence interval) if normally distributed and as median and interquartile range (IQR) if not. Proportions are expressed as percentages. Baseline covariates were dichotomized as specified in Table 1 . To increase comparability of groups, partial exact PS matching was utilized. Patients were first matched exactly according to gender, and subsequently nearest-neighbour 1-to-1 propensity score matching without replacement for treatment vs control cases was performed separately on both gender groups.
An iterative approach was used to model the propensity score by logistic regression such that the best balance among groups was obtained. The final model for the propensity score calculation of Cohort I had a c-statistic of 0.845, and the P-value of the Hosmer and Lemeshow goodness-of-fit test was 0.14. The c-statistic of the final model used for Cohort II was 0.96, and the P-value of the Hosmer and Lemeshow goodness-of-fit test was 0.88. Both propensity score models included the following preoperative data: sex, body mass index, glomerular filtration rate, Society of Thoracic Surgeons risk score, delta P mean , ejection fraction, aortic regurgitation ≥2+, mitral regurgitation ≥2+, tricuspid regurgitation ≥2+, NYHA ≥III, history of syncope, history of acute cardiac decompensation, insulin-dependent diabetes, chronic obstructive pulmonary disease (COPD), arterial hypertension, coronary artery disease (CAD), myocardial infarction, hypercholesterolaemia, peripheral arterial occlusive disease, internal carotid artery (ICA) stenosis, any type of stroke, atrial fibrillation, prior pacemaker implantation, prior percutaneus coronary intervention and any previous cardiac surgery. In addition, the propensity score for Cohort II included the Agatston score of the aortic valve and the systolic effective aortic annulus diameter (CT based).
Balance checking before and after matching, sample average treatment effect for the treated estimation and test statistics calculation were performed using the Matching package [10] .
A two-tailed P-value of <0.05 was considered significant. Statistical analyses were performed using R 3.01 (R Development Core Team. R: A Language and Environment for Statistical Computing 2011); plots were created with the ggplot2 package [11] .
RESULTS
Cohort I (all patients)
Propensity score matching. Unadjusted baseline characteristics of all n = 128 patients are given in Table 1 (left column). Propensity score matching resulted in 40 matched pairs (right column). Propensity score matching yielded good bias reduction as shown in Fig. 2 . The absolute standardized mean difference of all covariates was <0.2, indicating good balance. Especially highly unbalanced covariates such as sex, history of stroke and insulindependent diabetes were effectively balanced in the matched pairs.
Functional results. Antegrade crossing of the stenotic native valve was feasible in all no-BAV patients without any events. All valves were implanted successfully. Table 2 summarizes the outcomes. There were no significant differences in the primary end points of aortic valve incompetence ≥2+, stroke, TIA, requirement for redilatation and necessity for new-onset pacemaker implantation. As expected, fluoroscopy time was significantly lower in no-BAV patients. Other outcome variables were not different between groups. In particular, transvalvular mean gradients did not differ in patients with or without BAV.
Cohort II (Agatston score analysis available)
Propensity score matching. Cohort II is a subset of all patients for whom high-quality complete cardio-CT data were available, allowing exact Agatston score calculation of the aortic valve calcification. Unadjusted baseline characteristics are given in Table 3 (left column). To further adjust for potential differences in valve calcification, the Agatston score was added to the propensity score utilized for matching within Cohort II (right column). Again, matching resulted in bias reduction (Fig. 3) . The absolute standardized mean difference of all covariates was <0.4, indicating moderate balance reduction.
Functional results. Even after adjustment, including adjusting for native valve calcification severity, no significant differences were visible with regard to valve performance or requirement for balloon redilatation (Table 4) . However, a significantly higher rate of TIA in the BAV group was noted. There were no strokes in either group.
DISCUSSION
The technique of TAVI has seen a remarkable evolution during the last few years. Adoption of this still-new, alternative treatment option for high-risk elderly patients with AS has been especially rapid in countries where specific reimbursement became available relatively early [12] . In Germany, currently 30% of all patients diagnosed with degenerative AS undergo TAVI instead of conventional aortic valve replacement. The Edwards SAPIEN™ system was one of the very first TAVI devices on the market and allows TA antegrade as well as retrograde transvascular (transfemoral (TF), trans-subclavian (TS) and transaortic (TAo)) implantation. The valve itself underwent several iterations and is currently commercially available as SAPIEN XT™ in Europe. In parallel, the delivery systems also underwent significant modifications. For TF and TS, the main focus was to reduce the required sheath diameters. In order to ease retrograde crossing of the stenotic aortic valve in an TAo approach, the Ascendra II™ delivery system, which is used for both TA and TAo approaches, recently underwent further development that resulted in the Ascendra II+™ system. This new version of delivery catheter adds a nose cone, which enables a smoother transition from the tip over the crimped valve onto the integrated 'pusher'. Thus, direct crossing of the stenotic valve without BAV seems feasible although it is not officially recommended.
The main purpose of BAV prior to implantation of a SAPIEN™ valve is to 'open up' the stenotic valve in order to allow safe access with the valve system itself. This technique has been common 
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practice since the very early days of TAVI. On the other hand, the concept has never been questioned, and thus, the true value of BAV is unknown. Theoretically, a technique using 'direct valve stenting' by omitting the BAV step would further simplify the procedure and result in less manipulation within the calcified aortic valve. As shown in transcranial Doppler studies, BAV can result in cerebral embolism [13, 14] ; therefore, a no-BAV approach could even be associated with lower rates of neurological events.
Recently, it has been shown that valve implantation with the CoreValve™ (Medtronic, USA) prosthesis is feasible without prior BAV [15, 16] . There are several differences between that system and the SAPIEN XT™ system, however, they do not allow direct comparison. Briefly, the outer diameter of the CoreValve™ delivery catheter is significantly smaller and the sheath completely covers the loaded valve. Thus, there seems to be no risk of a potential dislodgement of the valve on the delivery catheter due to potential friction in cases of difficult valve crossing. Furthermore, the CoreValve™ system can easily be taken out through the delivery sheath in case of unsuccessful valve crossing, whereas this is cumbersome when using the SAPIEN XT™ system ('point of no return'). On the other hand, the SAPIEN™ concept relies on active balloon inflation for anchoring, which will result in unmatched radial forces. From a different perspective, one could argue that the implantation of a SAPIEN™ prosthesis always incorporates a BAV and a post-ballooning step. Hence, once valve crossing has been accomplished, the functional result should not be affected.
Taking these factors into consideration, we decided to change to a direct valve-stenting technique when implanting the SAPIEN XT™ prosthesis over the antegrade TA approach shortly after the new Ascendra II+™ system became available. To evaluate this new technique, we compared the results without BAV with those from historical patients where BAV was still used. Propensity score matching was utilized to adjust for baseline values (Cohort I). Overall, there were no relevant differences detectable except for a shorter fluoroscopy time. Antegrade valve crossing was possible without any problems in all patients and the ability to perform fine adjustments in order to achieve the most optimal position during a step-wise technique was preserved in all no-BAV patients. Furthermore, no differences were observed with regard to potential haemodynamic compromises when positioning the valve within the native valve not predilated by BAV.
The funnel-like configuration of the native stenotic valve when approaching from the ventricular side (TA approach) might be one reason why crossing of the valve was found to be extremely smooth. Whether a no-BAV technique would also be feasible for the retrograde transvascular approach and cases with a heavily calcified valve will have to be evaluated.
To further assess the potential influence on the functional outcomes of the valve calcification burden, the Agatston score was added to PS matching in Cohort II. Again, no differences with regard to functional outcomes were apparent. Thus, at least in our limited experience, the technique of direct valve stenting appears to be feasible and safe and to have no negative effect on functional outcomes.
Interestingly, neurological events were significantly less frequent in the no-BAV group in Cohort II. Although this does make sense from a theoretical perspective, it has to be pointed out that PS matching resulted in an unbalanced rate of ICA stenosis. Since ICA stenosis is associated with TIA and this covariate is the only one that is rather unbalanced in the matched data set, we analysed the coincidence of ICA stenosis and TIA in both groups. In the no-BAV group, 2 of 25 patients were diagnosed with ICA stenosis, whereas in the control (BAV) group 7 of 25 patients had a history of ICA stenosis. Of those 7 patients, 2 actually developed a TIA after the TA-AVI procedure. Within the control group, however, the relationship between having a history of ICA stenosis and subsequent development of a TIA after the surgery was not significant (P = 0.55). In summary, the overall stroke rate was extremely low in all groups, which has been shown to be consistently associated with the TA approach [17] . The observation of a lower TIA rate in the no-BAV group of Cohort II is certainly interesting but should not be over-interpreted given the unbalanced ICA rate mentioned above.
A limitation of our study is the relatively small patient sample size. In addition, PS matching has been shown to be a reliable statistical method [18] but in general is inferior to a prospective randomized trial as PS matching cannot adjust for any potential unknown/unmeasured confounder [19] . It has been shown, however, that even studies with small sample size can yield correct estimations of treatment effects using PS matching [20] . Furthermore, our experience reflects 'real-world' patients in an allcomers fashion rather than a selected trial population.
Nevertheless, a larger trial or registry would be highly welcomed to further evaluate this new and exciting technique of TA direct valve stenting, as this modification might be associated with a lower rate cerebral embolism and clearly simplifies the procedure.
CONCLUSION
Direct valve stenting is feasible and safe using an antegrade TA approach. The technique further simplifies the procedure indicated by a significantly shorter fluoroscopy time and may be associated with less risk of cerebral embolism. Omitting the BAV does not affect the functional outcomes by any means. Based on our experience, direct valve stenting has become our routine approach for all TA-AVI procedures using the SAPIEN XT™ prosthesis.
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